Since several studies document a decrease in adherence as therapeutic complexity increases, an improvement in therapeutic adherence can be expected with the use of this drug, especially considering the excellent results that patients can achieve in terms of weight reduction
First, muscle loss lowers your resting metabolic rate, which means you burn fewer calories at rest making weight regain more likely if you ever stop the medication
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): A phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Half were outright nondelivery scams
Second, if you're weighing compounded versus brand-name, the regulatory trajectory is part of that math, because an FDA-approved brand-name product isn't subject to the same compounding uncertainty
Always start low and listen to your body